Growth and Safety Clinical Trial on a New Infant Formula.

Nara Organics

Status

Completed

Conditions

Healthy Growth

Treatments

Other: Organic Infant Formula

Other: Control Infant Formula

Study type

Interventional

Funder types

Industry

Identifiers

NCT04671576

NA-101-19

Details and patient eligibility

About

The aim of the study is to assess age-appropriate growth of healthy infants fed a new organic milk-based infant formula.

Full description

A 16-weeks length, randomized, controlled, double-blind, parallel study designed to evaluate growth and tolerance of healthy infants fed milk-based infant formula. The study has been designed in accordance with Good Clinical Practice guidelines and the requirements of the Code of Federal Regulations 21 CFR 106.96

Enrollment

176 patients

Sex

All

Ages

1 to 14 days old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Healthy gestational term (≥ 37 wks; ≤ 41 wks and 6 days).
Birth weight of ≥ 2,500 g and ≤ 4,500 g.
Postnatal age ≤ 14 days.
Singleton.
Designated as healthy, that is no recognized diseases.
Weight, length, weight-for-length, and head circumference within ≥ 5th and ≤ 95th percentile for age-sex according to World Health Organization (WHO) growth standards (birth to 24 months).
Exclusive feeding and tolerating cow milk formula at time of enrollment.
Parent(s) or legal guardians are willing and able to feed the assigned formula as sole source of nutrition.
Parent(s) or legal guardians are willing and able to participate in anthropometric procedures.
Parent(s) or legal guardians have voluntarily signed and dated required participation forms, such as the ICF approved by an IRB.

Exclusion criteria

An infant from a multiple birth, such as twin, triplet, or the like.
Personal or immediate family history of cow-milk protein allergy or intolerance.
Currently on any medication to treat growth failure or that may significantly impact growth.
Evidence of any anatomic and/or physiologic condition that would interfere with normal growth, development, or feeding, such as genetic, neurological, gastrointestinal, cardiac, pulmonary, hepatic, or renal.
A maternal history with known adverse effects on the fetus and/or the newborn infant, such as positive HIV, insulin-dependent diabetes, opioid exposure during pregnancy.
Enrolled in another clinical trial involving a drug, nutrition supplement, device, or intervention.